Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 7, 2015, Pages 2064-2067

  Hamada, Yukihiro ^a,b   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Penetration; Population pharmacokinetics; Skin infections; Staphylococcus aureus

Indexed keywords

VANCOMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PENETRATION; DRUG TISSUE LEVEL; HUMAN; INTERSTITIAL FLUID; LIMB DISEASE; LIMB INFECTION; MICRODIALYSIS; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PREDICTION; TISSUE WATER;

EID: 84936950647     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv074     Document Type: Article

References (14)

1. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2009; 3: e18-55.
2. Bulik CC, Wiskirchen DE, Shepard A et al. Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. Antimicrob Agents Chemother 2010; 54: 5209-13.
3. Wiskirchen DE, Shepard A, Kuti JL et al. Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis. Antimicrob Agents Chemother 2011; 55: 4170-5.
4. Skhirtladze K, Hutschala D, Fleck Tet al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 2006; 50: 1372-5.
5. Payne CJ, Thomson AH, Stearns AT et al. Pharmacokinetics and tissue penetration of vancomycin continuous infusion as prophylaxis for vascular surgery. J Antimicrob Chemother 2011; 66: 2624-7.
6. Housman ST, Bhalodi AA, Shepard A et al. Vancomycin tissue pharmacokinetics in patients with lower limb infections via in vivo microdialysis. J Am Podiatr Med Assoc 2014; in press.
7. Neely MN, van Guilder MG, YamadaWMet al. Accurate detection of outliers and subpopulations with Pmetrics, a non-parametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 2012; 34: 467-76.
8. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978; 6: 165-75.
9. Crandon JL, MacVane SH, Nicolau DP. Clinical laboratory-based assay methodologies may underestimate and increase variability of vancomycin protein binding in hospitalized patients. Pharmacotherapy 2014; 34: 203-9.
10. Rybak MJ, Lomaestro BM, Rotschafer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 3: 325-7.
11. Barbour A, Scaglione F, Derendorf H. Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/ pharmacodynamic indices. Int J Antimicrob Agents 2010; 35: 431-8.
12. Richter SS, Diekema DJ, Heilmann KP et al. Activities of vancomycin, ceftaroline, and mupirocin against Staphylococcus aureus isolates collected in a 2011 national surveillance study in the United States. Antimicrob Agents Chemother 2014; 58: 740-5.
13. Mendes RE, Sader HS, Flamm RK et al. Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program. Antimicrob Agents Chemother 2014; 58: 2921-4.
14. Housman ST, Sutherland CA, Nicolau DP. Pharmacodynamic profile of commonly utilized parenteral therapies against methicillin-susceptible and methicillin-resistant Staphylococcus aureus collected from US hospitals. Int J Antimicrob Agents 2014; 44: 235-41.